newsfilter
← Latest News
GlobeNewswire·

Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates

FDA End-of-Phase 2 meeting for pilavapadin in DPNP to be held by year-end All IND-enabling studies of LX9851 for obesity completed and submitted to licensee Novo Nordisk Site initiation for SONATA-HCM Phase 3 study